<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561531</url>
  </required_header>
  <id_info>
    <org_study_id>148/2563</org_study_id>
    <nct_id>NCT04561531</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.</brief_title>
  <official_title>Efficacy and Safety of Intermittent Bolus Comparing With Traditional Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia at Rajavithi Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare between intermittent bolus and traditional continuous drip of 3%NaCl in patients&#xD;
      with severe symptomatic hyponatremia in Rajavithi Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Hyponatremia is the most common electrolyte imbalance in clinical practice,&#xD;
      associated with increased mortality and length of stay. In 2014,European guideline have&#xD;
      recommended promp infusion of 3%NaCl 150 ml in 20 minutes to raise plasma Na to 5 mmol/L and&#xD;
      improve symptoms. The recommendation was the result of studies with small numbers of&#xD;
      patients, and expert opinions.&#xD;
&#xD;
      Methods: A single center opened-label randomized controlled-trial,we will randomly assign 40&#xD;
      patients with severe symptomatic hyponatremia (plasmaNa&lt;125mmol/L) in Rajavithi Hospital into&#xD;
      two groups:&#xD;
&#xD;
      First group receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and follow plasma&#xD;
      sodium until achieve target of goal plasma sodium = 5 mmol/L in 6 hours (no more than 12&#xD;
      mmol/L in 24 hr and 18 mmol/L in 48 hr),another receive traditional continuous drip of 3%NaCl&#xD;
      start with rate = 1ml/kg/hr and follow plasma sodium every 1 hour until achieve target of&#xD;
      plasma sodium 5 mmol/L in 6 hours .The primary end point is change in plasma sodium in 6&#xD;
      hours and improvement of glasglow coma scale.The secondary end points are change in plasma&#xD;
      sodium in 24,48 hours,overcorrection rate in 24 and 48 hours ,ODS rate ,hospitality days and&#xD;
      mortality rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma sodium and glasglow coma scale(GCS)</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in plasma sodium and level of consciousness (GCS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma sodium and glasglow coma scale(GCS)</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Change in plasma sodium and level of consciousness (GCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overcorrection rate</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>rate of overcorrection which defined as change in plasma sodium over 12 mmol/L in 24 hr and 18 mmol/L in 48 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODS rate</measure>
    <time_frame>in 7 days</time_frame>
    <description>rate of osmotic demyelinating syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitality days</measure>
    <time_frame>until discharge</time_frame>
    <description>hospitality days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>in 30 days</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Osmotic Demyelination Syndrome</condition>
  <arm_group>
    <arm_group_label>Intermittent bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional continuous drip</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3%NaCl</intervention_name>
    <description>Intervention is infusion of 3%NaCl which is defined in arms of experiment.</description>
    <arm_group_label>Intermittent bolus</arm_group_label>
    <arm_group_label>Traditional continuous drip</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in Rajavithi Hospital&#xD;
&#xD;
          -  Age from 18 years&#xD;
&#xD;
          -  Plasma Na &lt; 125 mmol/l with glucose-corrected&#xD;
&#xD;
          -  Severe symptomatic hyponatremia (Vomitting ,Coma ,Somnolence)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic BP &lt; 90 mmHg Or MAP&lt; 70 mmHg&#xD;
&#xD;
          -  Pregnancy or Lactation&#xD;
&#xD;
          -  Congestive Heart Failure or Volume overload&#xD;
&#xD;
          -  Lung congestionfrom CXR&#xD;
&#xD;
          -  Chronic renal failure patients with edema&#xD;
&#xD;
          -  Cirrhosis patients with edema&#xD;
&#xD;
          -  Patients with coronary artery disease&#xD;
&#xD;
          -  Patients with brain injuries&#xD;
&#xD;
          -  Deny consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Orakan Lanwong</last_name>
    <phone>0803625252</phone>
    <email>orakanpor@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kumtorn Lelamali</last_name>
    <phone>0967816239</phone>
    <email>lelamali01@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.jscimedcentral.com/BrainScience/brainscience-1-1004.pdf</url>
    <description>7. Mohamed OH, Abdallah N. Prevention and treatment of the osmotic demyelination syndrome: JSM Brain Sci 2016; 1: 1004.</description>
  </link>
  <link>
    <url>https://www.aerzteblatt.de/int/archive/article/209401/Central-pontine-myelinolysis-and-osmotic-demyelination-syndrome</url>
    <description>14. Lambeck J, Hieber M, Dre√üing A, Niesen WD. Central pontine myelinolysis and osmotic demyelination syndrome. Dtsch Arztebl Int. 2019; 116: 600-6.</description>
  </link>
  <reference>
    <citation>King JD, Rosner MH. Osmotic demyelination syndrome. Am J Med Sci. 2010 Jun;339(6):561-7. doi: 10.1097/MAJ.0b013e3181d3cd78. Review.</citation>
    <PMID>20453633</PMID>
  </reference>
  <results_reference>
    <citation>Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014 Feb 25;170(3):G1-47. doi: 10.1530/EJE-13-1020. Print 2014 Mar. Erratum in: Eur J Endocrinol. 2014 Jul;171(1):X1.</citation>
    <PMID>24569125</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med. 1987 Nov 5;317(19):1190-5. Review.</citation>
    <PMID>3309659</PMID>
  </results_reference>
  <results_reference>
    <citation>Adrogu√© HJ, Madias NE. Hyponatremia. N Engl J Med. 2000 May 25;342(21):1581-9. Review.</citation>
    <PMID>10824078</PMID>
  </results_reference>
  <results_reference>
    <citation>Ball SG, Iqbal Z. Diagnosis and treatment of hyponatraemia. Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):161-73. doi: 10.1016/j.beem.2015.12.001. Epub 2015 Dec 30. Review.</citation>
    <PMID>27156756</PMID>
  </results_reference>
  <results_reference>
    <citation>Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009 May;29(3):282-99. doi: 10.1016/j.semnephrol.2009.03.002. Review.</citation>
    <PMID>19523575</PMID>
  </results_reference>
  <results_reference>
    <citation>Koenig MA, Bryan M, Lewin JL 3rd, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hypertonic saline. Neurology. 2008 Mar 25;70(13):1023-9. doi: 10.1212/01.wnl.0000304042.05557.60. Epub 2008 Feb 13.</citation>
    <PMID>18272864</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoorn EJ, Zietse R. Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines. J Am Soc Nephrol. 2017 May;28(5):1340-1349. doi: 10.1681/ASN.2016101139. Epub 2017 Feb 7. Review.</citation>
    <PMID>28174217</PMID>
  </results_reference>
  <results_reference>
    <citation>Garrahy A, Dineen R, Hannon AM, Cuesta M, Tormey W, Sherlock M, Thompson CJ. Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD. J Clin Endocrinol Metab. 2019 Sep 1;104(9):3595-3602. doi: 10.1210/jc.2019-00044.</citation>
    <PMID>30882872</PMID>
  </results_reference>
  <results_reference>
    <citation>George JC, Zafar W, Bucaloiu ID, Chang AR. Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia. Clin J Am Soc Nephrol. 2018 Jul 6;13(7):984-992. doi: 10.2215/CJN.13061117. Epub 2018 Jun 5.</citation>
    <PMID>29871886</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007 Nov;2(6):1110-7. Epub 2007 Oct 3.</citation>
    <PMID>17913972</PMID>
  </results_reference>
  <results_reference>
    <citation>Owen BE, Rogers IR, Hoffman MD, Stuempfle KJ, Lewis D, Fogard K, Verbalis JG, Hew-Butler T. Efficacy of oral versus intravenous hypertonic saline in runners with hyponatremia. J Sci Med Sport. 2014 Sep;17(5):457-62. doi: 10.1016/j.jsams.2013.09.001. Epub 2013 Sep 18.</citation>
    <PMID>24148616</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee A, Jo YH, Kim K, Ahn S, Oh YK, Lee H, Shin J, Chin HJ, Na KY, Lee JB, Baek SH, Kim S. Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial). Trials. 2017 Mar 29;18(1):147. doi: 10.1186/s13063-017-1865-z.</citation>
    <PMID>28356136</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

